Tratamiento adyuvante en el cáncer de mama operable

6Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Breast cancer(BC) is the most frequent neoplasm in women of the west countries. The treatment of BC is very complex, and include the combination of surgery, chemotherapy, radiotherapy, hormonetherapy and immunotherapy. Surgery is the gold standard in the radical treatment of BC. Anthracyclines and taxanes are very important in the adjuvant treatment of BC. These drugs have shown an increased disease-free-survival and overall survival in several studies. Tamoxifen has been the gold standard adjuvant hormonetherapy for the treatment of postmenopausal women with hormone-receptor-positive early BC for many years, but the third-generation aromatase inhibitors (letrozole, anastrozole, and exemestane) are now recommended as the preferred therapy. Trastuzumab in combination with adjuvant chemotherapy has changed the natural history of early Her-2 positive BC. New drugs are under investigation in the treatment of BC. Copyright © 2008 Aran Ediciones, S.L.

Cite

CITATION STYLE

APA

Khosravi Shahi, P., Izarzugaza Perón, Y., Encinas García, S., Díaz De La Muñoz Espada, V. M., & Pérez Manga, G. (2008, January). Tratamiento adyuvante en el cáncer de mama operable. Anales de Medicina Interna. https://doi.org/10.4321/s0212-71992008000100010

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free